Reconstructing the immune system with lentiviral vectors
Authors:
Open Access
- 25 July 2017
- journal article
- review article
- Published by Springer Nature in Virus Genes
- Vol. 53 (5) , 723-732
Abstract
Lentiviral vectors (LVs) developed in the past two decades for research and pre-clinical purposes have entered clinical trials with remarkable safety and efficacy performances. Development and clinical testing of LVs for improvement of human immunity showed major advantages in comparison to other viral vector systems. Robust and persisted transduction efficiency of blood cells with LVs, resulted into a broad range of target cells for immune therapeutic approaches: from hematopoietic stem cells and precursor cells for correction of immune deficiencies, up to effector lymphoid and myeloid cells. T cells engineered for expression of chimeric antigen receptors (CARs) or epitope-specific transgenic T cell receptors (TCRs) are in several cancer immune therapy clinical trials worldwide. Development of engineered dendritic cells is primed for clinical trials for cancer and chronic infections. Technological adaptations for ex vivo cell manipulations are here discussed and presented based on properties and uses of the target cell. For future development of off-shelf immune therapies, direct in vivo administration of lentiviral vectors is warranted and intended. Approaches for lentiviral in vivo targeting to maximize immune therapeutic success are discussed.Keywords
Funding Information
- DFG (DFG/ SFB738 Project A6; DFG/ REBIRTH Unit 6.4)
- DZIF (DZIF-TTU07.803)
This publication has 58 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene TherapyJournal of Immunotherapy, 2013
- Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1 + Acute Myeloid LeukemiaHuman Gene Therapy, 2013
- Dendritic Cell-Directed Vaccination with a Lentivector Encoding PSCA for Prostate Cancer in MicePLOS ONE, 2012
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Preconditioning Therapy with Lentiviral Vector-Programmed Dendritic Cells Accelerates the Homeostatic Expansion of Antigen-Reactive Human T Cells in NOD.Rag1 −/− .IL-2rγc −/− miceHuman Gene Therapy, 2011
- Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cellsGene Therapy, 2011
- Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy ApplicationHuman Gene Therapy, 2011
- Self-inactivating Gammaretroviral Vectors for Gene Therapy of X-linked Severe Combined ImmunodeficiencyMolecular Therapy, 2008
- Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapyJournal of Clinical Investigation, 2007